AzTrials
AzTrials

Severe Acute Respiratory FailureNCT01936207

Intensive Care - GLObal Study on Severe Acute Respiratory Infection

An observational study of Severe Acute Respiratory Failure, run by European Society of Intensive Care Medicine at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

IC-GLOSSARI (The Intensive Care GLObal Study on Severe Acute Respiratory Infection) is a multicentre, prospective, observational,14-day inception cohort study designed and conducted by the ESICM Trials Group to investigate the epidemiology and microbiology profiles of ICU-SARI, document commonly used treatment and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Severe Acute Respiratory Failure
How many people
800 participants
Where
1 siteBelgium
Study dates
Nov 2014to Nov 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: patients with ICU-SARI

Who may be able to join

  • Admitted to an Intensive Care Unit due to respiratory tract infection
  • Recent onset (within 7 days prior to ICU admission) of at least one of the following manifestations: dyspnea, fever (≥ 38°C, possible, probable or microbiologically confirmed respiratory tract infection

Who cannot join

  • Patients less than 18 years of age
  • Patients in whom the pneumonia cough and dyspnoea have been present for over seven days
  • Any patients who are on invasive (through an endotracheal tube) mechanical ventilation prior to admission for any reason other than general anaesthesia for surgical procedures.
  • Any patients previously included in the study during the same study period

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • All Centres Willing to Contribute Are Welcome

    Brussels

Other trials in Belgium

About this study

Official title: A Multi-centre, International 14-day Inception Cohort Study of Severe Acute Respiratory Infections on the Intensive Care Unit

IC-GLOSSARI (The Intensive Care GLObal Study on Severe Acute Respiratory Infection) is a multicentre, prospective, observational,14-day inception cohort study designed and conducted by the ESICM Trials Group to investigate the epidemiology and microbiology profiles of ICU-SARI, document commonly used treatment and monitoring strategies, measure current outcomes and identify potential topics for multidisciplinary studies ranging from interventional clinical trials to fundamental mechanisms of disease.

The purpose of this study is to answer the following questions:

What is the frequency and disease burden of SARI for ICU's worldwide? What are the aetiologies of ICU SARI? How are SARI patients diagnosed and managed in the ICU? What is the outcome from SARI in the ICU? Is there a difference in outcomes from SARI depending on the aetiology of the disease? Can we identify high-risk categories of SARI that could constitute a defined population for an interventional study?

Read the detailed description

Following the recent outbreaks of SARS and H1N1 influenza infections, there has been a significant interest in the surveillance of patients with severe acute respiratory infections (SARI), defined by the World Health Organisation (WHO) as an acute respiratory illness of recent onset (within 7 days) manifested by fever (≥ 38°C), cough, and dyspnea requiring overnight hospitalization.

Whereas this definition of SARI may prove practical to mount sentinel SARI surveillance systems, it is unlikely to provide relevant information for intensive care physicians regarding the nature of infections, the spectrum of severity, or the diagnostic and treatment strategies used for the subset of patients that are ultimately admitted to intensive care units. Only a subset of the SARI patients as defined by WHO will require ICU admission for oxygen therapy or positive pressure ventilation; a smaller subset will develop an acute respiratory distress syndrome (ARDS) and an even smaller proportion will require adjunctive treatments such as nitric oxide, ECMO, use of prone position or high frequency oscillation (HFO). Obtaining accurate information on the epidemiology of ICU-SARI and how these patients are currently diagnosed and treated will help us to understand the factors associated with progression from acute respiratory infections to the most severe forms of critical illness such as ARDS, septic shock, or multiple organ failure.

We thus aim to undertake a prospective, observational, inception cohort study to investigate the epidemiology and microbiology profiles of ICU-SARI, document commonly used treatment and monitoring strategies, measure current outcomes and identify potential topics for multidisciplinary studies ranging from interventional clinical trials to fundamental mechanisms of disease.

Fourteen day international inception cohort study of adult (≥18 years) patients presenting with SARI on admission to the ICU (ICU-SARI).

The study will be performed over 4 weeks. Each centre will include patients for 2 weeks, one in November and the other in January.

First week: 3 - 9 Nov 2013

Second week: 10-17 Nov 2013

Third week: 13-19 Jan 2014

Fourth week: 20-26 Jan 2014

To be eligible patients must have ICU-SARI as defined by the following

  1. Admitted to an Intensive Care Unit due to respiratory tract infection
  2. Recent onset (within 7 days prior to ICU admission) of at least one of the following manifestations:
  • Dyspnea
  • Fever (≥ 38°C)
  • Possible, probable or microbiologically confirmed respiratory tract infection

The following will be excluded from the study:

Patients less than 18 years of age Patients in whom the pneumonia cough and dyspnoea have been present for over seven days Any patients who are on invasive (through an endotracheal tube) mechanical ventilation prior to admission for any reason other than general anaesthesia for surgical procedures.

Any patients previously included in the study during the same study period Data collection will start on admission to the ICU and will continue on a daily basis in the ICU for a maximum of 28 days. The vital status at day 60 will be recorded (discharge, alive in the ICU, dead) so long as the patients is still hospitalized.

For a subgroup of investigator on a voluntary basis, the end-point will be extended to day 90 and day 180.

This international study aims to recruit as many centres as possible. A network of national coordinators will be identified. It will be the task of this group of individuals to enrol sites within their own country, to ensure the necessary regulatory approvals are in place and to coordinate the national communication.

ICU will be defined as a unit able to provide positive pressure ventilation and continuous monitoring of hemodynamic and respiratory variables. Recruitment of participating ICUs will be done through advertising of the study to ICUs registered in the ERIC; ICUs registered in the ESICM databases (membership \& congresses, H1N1 registry, EuSOS, Euro-BACT; ICUs registered in SAPS 3; ICUs registered in VENTILA.

We also plan to seek participation from ICUs of other research networks that may be interested in a joint research effort on this topic (Sepnet, Capnetz, GiVITI, ICNARC, CCCTG, ANZICS, SPCI).Through a study specific web site. And through advertising at National and international meetings.

Keywords
acute, respiratory, syndrome, prognosis, outcome research, respiratory infection, sepsis, organ failure
Medical subject headings
Syndrome, Respiratory Tract Infections, Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01936207
Study groupRoleWhat they receive
One GroupNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 60-day-inhospital death

    Measured: One week

Secondary outcomes (1)
  1. ICU mortality.

    Measured: One week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2013 (estimated)
  2. Study startNov 2014
  3. Primary completionNov 2014
  4. Study completionNov 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
800 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01936207
Sponsor's protocol ID
IC-GLOSSARI
Status last verified
Dec 2014
First submitted
2 Sep 2013
Last updated
11 Dec 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Severe Acute Respiratory Failure, run by European Society of Intensive Care Medicine at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

60-day-inhospital death (time frame: One week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in